What's New in Atopic Dermatitis and Itch Treatment?
By
Masterclasses in Dermatology
FEATURING
Gil Yosipovitch
By
Masterclasses in Dermatology
FEATURING
Gil Yosipovitch
574 views
March 6, 2024
Disclaimer: On September 13, 2024, the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), ...
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less
Comments 2
Login to view comments.
Click here to Login